Inter-Relationships of Cardinal Features and Outcomes of Symptomatic Pediatric Plasmodium falciparum Malaria in 1,933 Children in Kampala, Uganda (original) (raw)

Introduction

Children with malaria have a wide variety of signs and symptoms. The World Health Organization recognizes numerous hallmark features of severe malaria (Table 1).1 Acute malaria syndromes carry diagnostic value and prognostic importance, but do not occur with equal prevalence among different age groups and across different regions. The severity of clinical infection in malaria depends on complex interactions of host, parasite, and environmental factors.1

Table 1

World Health Organization features of malaria

Features
Clinical
Impaired consciousness or unrousable coma
Prostration (generalized weakness; unable to walk or sit up without assistance)
Failure to feed
Multiple convulsions (> 2 episodes in 24 hours)
Deep breathing, respiratory distress (acidotic breathing)
Circulatory collapse or shock (systolic blood pressure < 50 mm Hg in children)
Clinical jaundice plus evidence of other vital organ dysfunction
Hemoglobinuria
Abnormal spontaneous breathing
Pulmonary edema (radiologic)
Laboratory findings
Hypoglycemia (blood glucose level < 2.2 mM)
Metabolic acidosis (plasma bicarbonate level < 15 mM)
Severe normocytic anemia (hemoglobin level < 5 g/dL)
Hemoglobinuria
Hyper-parasitemia (> 2% or 100,00 parasites/μL in low-intensity transmission areas or > 5% or 250,00 parasites/μL in areas of high, stable malaria transmission intensity
Hyper-lactatemia (lactate level > 5 mM)
Renal impairment (serum creatinine level > 265 μmol/L)

Numerous previous studies have analyzed clinical features in malaria. Early work by Marsh and others established that three overlapping syndromes were found in severe disease: cerebral malaria (CM), respiratory distress (RD), and severe malaria anemia (SMA).2,3 Subsequent reports further characterized the clinical findings of malaria and established fundamental patterns of the illness.414 These patterns include the importance of impaired consciousness as a risk-factor for fatal outcome, the value of blood transfusion in the treatment of severe anemia, hypoglycemia during acute illness, and the observation of RD as a manifestation of lactic acidosis (LA). These studies were published more than 15 years ago and most were based on < 500 patients.

During 2000–2010, additional reports refined the case definitions of severe malaria. Two studies of children with severe malaria in Gabon and a third study from Mali reported that mortality was associated with CM, hypoglycemia, RD and LA.1517 These reports were unable to assess the contribution of increased blood lactate levels, thrombocytopenia, and leukocytosis to outcomes. Idro and others18 provided a detailed description of 100 children with CM treated in Uganda and identified RD, circulatory failure, hyporeflexia, and hyper-parasitemia as additive risk factors for fatal outcomes. In a subsequent report of more than 9,000 children in Kenya with malaria, they confirmed that acidosis, hypoglycemia, and circulatory collapse were associated with neurologic signs.19 Smaller studies from Ghana20 and Gabon21 and a multicenter sub-Saharan study22 further defined complications of severe disease. In a review of 25 previously published studies, Roca-Feltrer and others reported that the age distribution for SMA was consistently younger than that for CM.23 Recently, Vekemans and others24 provided a thorough review of the published literature through 2010 and suggested a standardized case definition for severe malaria for use in a multicenter phase III vaccine trial. Their report provides the most up-to-date approach to classifying severe malaria on the basis of previously available data.

In this report, we present results of a prospective observational study of clinical and laboratory features among 1,933 children with acute Plasmodium falciparum malaria at Mulago Hospital during 2007–2009. We used newer clinical assays, including blood lactate levels, oximetry, and complete blood counts. We present data on the prevalence of major malaria syndromes; the impact of specific syndromes on case-fatality rates; and, for the first time, a cluster analysis of the extent of association between different clinical features present in a large cohort of children with severe malaria. Our findings update the clinical description of severe malaria in children, respond to requests for improved case definitions for severe malaria,25 and may suggest new research targets and novel treatments for specific sub-groups of patients.

Methods

Study population.

Children 6 months to 12 years of age with either uncomplicated or severe malaria were enrolled in a prospective observational study conducted at the Acute Care Unit of Mulago Hospital in Kampala, Uganda.26 Mulago Hospital is a 1,500 bed national referral center and teaching hospital of Makerere University College of Health Sciences where a previous study documented a 4.2% case-fatality rate among 23,342 children with malaria.27 Children were enrolled during October 2007–October 2009. The diagnosis of malaria was suspected on the basis of clinical symptoms and a positive thick blood smear examined by an experienced laboratory technician, and subsequently confirmed by two expert reviewers from a reference parasitology laboratory who examined in a blinded fashion thick and thin blood smears from each person. Uncomplicated malaria was defined as the absence of any impairment of consciousness or hypoxia, with peripheral blood lactate levels < 5 mM and hemoglobin (Hb) levels > 7 g/dL without transfusion. Severe malaria was defined as impaired consciousness, arterial oxygen saturation < 90%, blood lactate levels > 5 mM, or an Hg level < 5 g/dL (or < 6 g/dL if tested after transfusion). Children who did not meet the above criteria for either uncomplicated or severe malaria were not enrolled in the study so that analysis would contrast the spectrum of malaria severity.

All enrolled persons were tested for infection with human immunodeficiency virus (HIV);26 forty-five were positive and were excluded from the analysis so that the clinical description would represent the effects of malaria alone. For each child, a parent or guardian provided written informed consent for participation in accordance with guidelines of the research ethics committees of the Makerere University College of Health Sciences and the University of Toronto.

Data collection.

Two physicians (CM and AD) experienced in malaria care of children enrolled, evaluated, and recorded all information. All available clinical resources were used to assess the presence of coexisting bacterial infection or other medical conditions. Commercially available devices were used to measure complete blood count (ACT*8; Beckman Coulter, Brea, CA), blood lactate (LactatePro LT-1710; Arkray, Kyoto, Japan), oxygen saturation (Nonin, Plymouth, MN), and glucose (Ascensia Contour; Bayer HealthCare LLC, Mishawaka, IN). The presence of Hb S was tested by using a commercial solubility assay (SickleDex; Streck, Omaha, NE). ABO and rhesus blood grouping was determined by using commercial reagents according to manufacturer's directions. Quantitative parasite counts were determined by two independent observers counting the number of parasitized erythrocytes indexed to 200 leukocytes and then corrected for the actual leukocyte count.26 Structured clinical data for each person were collected in a uniform fashion by using a case report form (CRF) (<www.cd36malaria.org>). Data from the hard-copy CRF was transferred to a digital CRF (prepared with FileMaker Pro 9.0 version 1; FileMake, Santa Clara, CA) for subsequent analysis. Data accuracy and quality control were performed as reported.26

Severe malaria categories.

On the basis of their clinical and laboratory results, children with severe malaria were assigned to one or more of the following categories: severe malaria anemia Hb level < 5 g/dL (or < 6 g/dL after transfusion); lactic acidosis: blood lactate level > 5 mM; severe thrombocytopenia: platelet count < 50,000/μL; leukocytosis: total leukocyte count > 10,000 cells/μL; hyper-parasitemia: > 5% of erythrocytes parasitized; hypoxia: peripheral oxygen saturation < 90% while breathing ambient air; and hypoglycemia: blood glucose level < 2.2 mM.

We categorized persons as having CM if they met both of the following two criteria. First, the patient had coma or a Blantyre Coma Scale ≤ 2 provided that the coma was present for > 6 hours and was not attributable to hypoglycemia, meningitis, non-malaria-related pre-existing neurologic abnormalities, or drugs such as anticonvulsants or other agents with sedative/hypnotic effects. Second, the patient met either or both of the following two severity criteria: the patient had > 3 of the following 10 World Health Organization severity criteria: 1) > 2 seizures in 24 hours, RD, jaundice, hemoglobinuria, spontaneous bleeding, hypoglycemia (glucose level < 2.2 mM), LA (lactate level > 5 mM), normocytic severe anemia, hyper-parasitemia >5%, or new acute renal failure; or 2) the patient had a cumulative score of ≥ 3 points on a previously reported scale of neurologic involvement.26

Statistical analysis.

Continuous data are reported as a median with inter-quartile ranges (IQRs), and were compared by using the Wilcoxon test. Categorical data were compared using the chi-square test. All comparisons were two-tailed and a P value < 0.05 was considered significant. Associations between pairs of categories of severe malaria are presented as odds ratios. Logistic regression was used to determine the odds ratios for the outcome of death using input terms found to have significant association with death in 2 × 2 analysis or known to have a published biologic relationship to adverse outcomes in malaria: presence of CM, hypoxia, severe thrombocytopenia, leukocytosis, LA, hyper-parasitemia, SMA, Hb S, blood group A, age < 1.5 years, and female sex. Of the 855 children with severe malaria, 798 had recorded values for the above 11 input terms and formed the basis for the regression. The enrollment of approximately 1,000 uncomplicated and 1,000 severe malaria patients was designed to detect a difference of ≥ 6% with 80% power between uncomplicated and severe malaria patients for clinical features with a prevalence of 25–50%.

Ethics.

The study was approved by the Makerere University School of Medicine Research Ethics Committee, the Toronto Academic Health Science Network Research Ethics Board, and the Uganda National Council for Science and Technology. The study was registered at <www.clinicaltrials.gov> as NCT00707200.

Results

A total of 2,092 children six months to 12 years of age with either uncomplicated malaria or severe malaria were enrolled. After study completion, 159 were excluded, leaving 1,933 available for analysis. Reasons for exclusion (specified before the study) were: HIV positivity (n = 45), not infected with P. falciparum (n = 35), and not meeting pre-study definitions for uncomplicated or severe disease (n = 79). Illness was attributed exclusively to malaria in nearly all children. For example, among those categorized as having CM (n = 174), one-third (n = 56) had a lumbar puncture performed and none of these children showed evidence of meningitis. Only 38 children received antibiotics for unconfirmed but suspected coexisting bacterial infections. Levels of parasitized erythrocytes were > 2,500/μL in 94% of children28 and > 5,000/μL in 91%.24

All patients were treated by pediatricians expert in malaria care. Intravenous quinine was used in 99% of children with severe malaria. Intravenous hydration, oxygen, and anti-seizure medications were used as needed. Transfusion therapy was readily available. Among 653 patients for whom blood was requested for transfusion, only one failed to receive a transfusion, three received fewer than the prescribed units, and 29 experienced some delay before the start of transfusion because of blood availability.

Clinical and laboratory features of 1,933 children are shown in Table 2. Of these children, 1,078 were classified as having uncomplicated malaria and 855 children were classified as having severe malaria on the basis of enrollment features of neurologic involvement, SMA, LA, or hypoxia. In addition to these enrollment features, children with severe malaria differed from those with uncomplicated malaria for 17 other clinical or laboratory findings. The age distribution of children is shown in Figure 1A. Severe malaria was more common among children < 1.5 years of age.

Table 2

Clinical and laboratory features among 1,933 children with uncomplicated or severe Plasmodium falciparum malaria, Kampala, Uganda*

Characteristic Uncomplicated malaria, n = 1,078 Severe malaria, n = 855 P
Value No. Value No.
History and physical examination
Age, years (range) 2.9 (1.6–5.1) 1,078 1.8 (1.1–3.1) 855 < 0.0001
Body mass index (range) 15.4 (14–17) 797 14.8 (13.6–16.5) 655 < 0.0001
Sex (F:M) 521:557 1,078 402:453 855 0.60
Days ill before hospitalization (range) 3 (2–4) 1,078 3 (3–5) 855 < 0.0001
Temperature, °C (range) 38.2 (37.3–39) 660 37.8 (37.1–38.6) 492 < 0.0001
Patients with palpable spleen 157 (23%) 676 310 (62%) 504 < 0.0001
Patients with respiratory distress 74 (7%) 1,078 518 (61%) 855 < 0.0001
Jaundice 19 (4.1%) 460 88 (26.5%) 332 < 0.0001
Coma 0 (0%) 1,078 200 (23%) 855 NA
Recurrent seizures 0 (0%) 1,078 196 (23%) 855 NA
Blantyre coma score (range) ND ND 4 (4–5) 844 NA
Laboratory values upon presentation, median (IQR)
Hemoglobin (g/dL) 9.3 (8.2–10.4) 1,078 4.5 (3.6–6.3) 855 NA
MCV (fL) 84 (78–89) 1,077 84 (78–90) 855 0.61
Platelet count (× 109/L) 136 (81–217) 1,078 103 (60–170) 854 < 0.0001
Leukocyte count (× 109/L) 7.8 (5.9–10.3) 1,072 11.1 (7.7–16.7)] 853 < 0.0001
Absolute monocyte count (× 109/L) 0.5 (0.3–0.8) 1,065 0.8 (0.5–1.4) 847 < 0.0001
Parasitized erythrocytes/μL × 1,000 83 (29–190) 1,063 91 (22–263) 831 0.13
% erythrocytes parasitized 2.2 (0.8–5.0) 1,062 4.6 (1.2–12.9) 831 < 0.0001
Hemoglobin S (%) 57 (6) 1,045 43 (5) 826 0.89
Glucose (mM) 5 (4.2–6) 65 5 (4.2–6.2) 248 0.65
Lactate (mM) 2.2 (1.6–3.0) 1,052 5.6 (3.1–8.3) 851 NA
Oximetry saturation (%) 99 (97–100) 1,052 97 (94–99) 849 NA
No. patients (%) with specific malaria syndromes
Cerebral malaria 0 (0) 1,078 174 (20) 855 NA
Lactic acidosis (> 5 mM) 0 (0) 1,052 482 (56) 851 NA
Severe malaria anemia (hemoglobin < 5 g/dL) 0 (0) 1,078 558 (65) 855 NA
Platelets < 50,000/μL 104 (10) 1,078 166 (19) 854 < 0.0001
Leukocytosis (leukocytes > 10,000/μL) 286 (27) 1,072 490 (57) 855 < 0.0001
Hyper-parasitemia (> 5% infected erythrocytes) 264 (25) 1,063 402 (48) 831 < 0.0001
Blood group A or AB 302 (28) 1,078 317 (37) 855 < 0.0001
Hypoxia (SaO2 < 90%) 0 (0) 1,052 43 (5) 849 NA
Hypoglycemia (< 2.2 mM) 0 (0) 65 22 (8.9) 248 < 0.0001
Death 0 (0) 1,078 48 (4.5) 855 < 0.0001

Figure 1.

Figure 1.

Figure 1.

Age distribution of children les than five years of age with severe malaria, Kampala, Uganda. A, Age distribution among children with uncomplicated versus severe malaria. B, Age distribution among children with cerebral malaria or severe anemia.

Citation: The American Society of Tropical Medicine and Hygiene 88, 4; 10.4269/ajtmh.12-0668

Clinical and laboratory features among the 855 children with severe malaria are shown in Table 3. The prevalence of findings for each of eight major clinical factors is shown.

Table 3

Clinical and laboratory features among 855 children with severe Plasmodium falciparum malaria, Kampala, Uganda*

Characteristic Cerebral malaria, n = 174 Lactic acidosis (lactate > 5 mM), n = 481 Anemia (hemoglobin < 5 g/dL), n = 558 Thrombocytopenia (< 50,000 platelets/μL), n = 166 Leukocytosis (> 10,000 leukocytes/μL), n = 490 Hyper-parasitemia (> 5% infected erythrocytes), n = 402 Hypoxia (< 90% SaO2), n = 43 Hypoglycemia (< 2.2 mM), n = 22
Value No. Value No. Value No. Value No. Value No. Value No. Value No. Value No.
History and physical examination
Age, years 2.5 (1.5–3.9) 174 1.70 ([1.1–3.0) 481 1.55 (1.0–2.6) 558 2.48 (1.4–4.0) 166 1.48 (1–2.5) 490 1.6 (1.1–2.9) 402 1.92 (1.0–3.1) 43 1.93 (1.3–3.3) 22
BMI 14.7 (13.3–16.7) 122 14.8 (13.7–16.5) 364 14.8 (13.6–16.2) 439 15.0 (13.8–16.5) 112 14.7 (13.5–16.3) 382 14.7 (13.4–16.6) 296 14.4 (13–16) 31 14 (12.7–16) 17
BMI lowest quartile (< 13.6) 39 (32) 122 86 (24) 364 113 (26) 439 25 (22) 112 102 (27) 382 79 (27) 296 9 (29) 31 7 (41) 17
Sex (F:M) 90:84 174 233:248 481 263:295 558 80:86 166 237:253 490 195:207 402 18:25 43 13:9 22
Days ill 3 (3–4) 174 3 (3–5) 481 4 (3–5) 558 3 (3–4) 166 4 (3–5) 490 3 (3–4) 402 4 (3–5) 43 3.5 (3–4) 22
Temperature, °C 37.9 (37.3–38.6) 82 38.0 (37.2–38.7) 301 37.8 (37–38.5) 321 37.9 (37.4–38.4) 102 37.8 (37–38.5) 294 37.9 (37.2–38.7) 245 37.8 (37–38.6) 22 37.8 (37.1–37.9) 11
Palpable spleen (%) 48 (55) 87 187 (60) 311 223 (68) 326 60 (57) 105 205 (68) 300 157 (63) 250 16 (70) 23 7 (64) 11
Respiratory distress (%) 125 (72) 174 367 (76) 481 339 (61) 558 112 (67) 166 342 (70) 490 286 (71) 402 42 (98) 43 21 (95) 22
Jaundice (%) 12 (20) 60 59 (27) 220 61 (28) 213 20 (27) 75 62 (31) 203 41 (24) 170 5 (31) 16 4 (40) 10
Coma (%) 171 (98) 174 103 (22) 470 56 (10) 558 65 (40) 164 98 (20) 487 99 (25) 402 14 (33) 43 17 (77) 22
Seizures (%) 135 (78) 174 113 (24) 470 65 (11.6) 558 55 (33) 164 105 (22) 487 103 (26) 402 15 (35) 43 11 (50) 22
Blantyre coma score 2 (2–2) 174 5 (4–5) 470 5 (5–5) 558 4 (2–5) 164 5 (4–5) 487 5 (4—5) 402 4 (4–5) 43 2 (2–3.75) 22
Patients with CM (%) 79 (16) 481 36 (6.4) 558 57 (34) 166 80 (16) 490 85 (21) 402 10 (23) 43 14 (64) 22
Laboratory values upon presentation
Lactate (mM) 4.3 (2.7–8.1) 171 8 (6.2–11.1) 481 4.9 (3.0–9.0) 556 7.0 (4.6–10.2) 165 6.05 (3.3–9.9) 488 6.4 (4.1–9.7) 401 9.7 (5.0–12.3) 43 10.0 (6.9–13.4) 22
Patients with lactate > 5 mM (%) 79 (47) 171 272 (49) 556 121 (73) 165 295 (60) 488 267 (67) 401 32 (74) 43 19 (86) 22
Hemoglobin, g/dL 6.9 (5.2–8.2) 174 4.6 (3.4–6.8) 481 3.8 (3.2–4.4) 558 5.9 (4.3–7.7) 166 4.1 (3.3–5) 490 4.6 (3.6–6.5) 402 4.6 (3.4–7.4) 43 4.75 (3.9–7.5) 22
Patients with hemoglobin ≤ 5 g/dL, (%) 36 (21) 174 272 (56) 481 69 (42) 166 370 (76) 490 253 (63) 402 23 (53) 43 12 (55) 22
MCV (fL) 84 (79–89) 174 83.5 (78–90) 481 85.5 (78–92) 558 84.4 (78–89) 166 83 (77–90) 490 84 (78–90) 402 84 (78–89) 43 82 (79–88) 22
Platelet (× 109/L) 73 (43–130) 174 90 (49–151) 481 120 (78–179) 558 34 (25–42) 166 118 (73–186) 490 85 (50–129) 402 92 (51–161) 43 90.5 (40–166) 22
Patients with platelet counts < 50,000/μL, (%) 57 (33) 174 121 (25) 481 69 (12) 558 68 (14) 490 100 (25) 402 11 (26) 43 8 (36) 22
Leukocytes (× 109/L) 9.4 ([7.1–14.3) 174 11.5 (8.1–18.2) 480 12.6 (8.5–18.8) 556 8.3 (5.4–13.9) 166 15.4 (12.2–21) 490 11.5 (8–17.4) 402 13.6 (9.5–20) 43 16 (10.4–21.2) 22
Patients with leukocyte counts > 10,000/μL, (%) 80 (46) 174 295 (61) 481 370 (66) 558 68 (41) 166 250 (62) 402 29 (67) 43 17 (77) 22
Monocytes (× 109/L) 0.6 (0.3–0.9) 174 0.81 (0.5–1.4) 480 1.02 (0.6–1.6) 556 0.46 (0.3–0.8) 166 1.2 (0.8–1.8) 490 0.82 (0.5–1.4) 402 0.74 (0.5–1.3) 43 0.86 (0.7–1.3) 22
Infected erythrocytes/μL (× 1,000) 124 (26–387) 171 137 (38–371) 471 68 (15–199) 538 197.5 (46–486) 162 91 (22–274) 480 269 (161–518) 402 137 (22–455) 41 151 (68–508) 21
% Infected erythrocytes 4.6 ([1.1–16.2) 171 7.0 (1.9–16.8) 471 4.2 (0.9–11.9) 538 7.6 (1.9–18.0) 162 5.5 (1.4–15.5) 480 13.6 (8.2–29.8) 402 6.3 (1.1–17.8) 41 7.7 (3.2–22.7) 21
Patients with > 5% infected erythrocytes (%) 85 (50) 171 267 (57) 471 253 (47) 538 100 (62) 162 250 (52) 480 22 (54) 41 14 (64) 21
Hemoglobin S 6 (4) 167 16 (3.4) 465 30 (5.5) 541 5 (3.1) 161 28 (5.9) 474 11 (2.8) 389 3 (7.1) 42 0 (0) 22
Patients with blood type A or AB 71 (41) 174 183 (38) 480 206 (37) 558 59 (35.8) 165 182 (37) 490 146 (36.3) 402 15 (36) 43 8 (36) 22
SaO2 saturation 96 (94–98) 171 96.5 (94–99) 477 97 (94–99) 555 96 (94–98) 163 97 (94–99) 486 96 (94–99) 398 84 (77–88) 43 95 (91–98) 21
Patients with SaO2 < 90%, (%) 10 (6) 171 32 (6.7) 476 23 (4.2) 554 11 (6.8) 163 29 (6) 485 22 (5.5) 397 4 (19) 21
Glucose (mM) 5.1 (4.3–6.9) 161 4.9 (3.7–6.1) 124 4.4 (3.6–5.4) 102 5.2 (4.2–6.8) 70 4.6 (3.6–5.4) 123 5.05 (4.1–6.4) 114 3.7 (2.2–7.8) 17 1.35 (0.9–1.9) 22
Patients with glucose < 2.2 mM, (%) 14 (8.7) 161 19 (15) 124 12 (11.8) 102 8 (11.4) 70 17 (13.8) 123 14 (12.3) 114 4 (24) 17
Deaths (%) 33 (19) 174 37 (7.7) 481 15 (2.7) 558 24 (14.5) 166 33 (6.7) 490 29 (7.2) 402 10 (23.3) 43 10 (45) 22

Cerebral malaria (n = 174).

Hypoglycemia was excluded as a cause of impaired consciousness in nearly all (93%) children categorized as having CM. Patients with CM were distinct from those with SMA; only 36 (4%) of 855 patients had both syndromes. As reported,23 children with CM were significantly older (median age = 2.5 years, IQR = 1.5–3.9 years) than those without CM (median age = 1.7 years, IQR = 1.0–2.9 years) (P < 0.0001) (Figure 1B). Among 855 patients with any form of SM, those with CM had a higher median Hb level (6.9 g/dL, IQR = 5.2–8.2 g/dL versus 4.2 g/dL, IQR = 3.4–4.9 g/dl; P < 0.0001) and a lower median platelet count (73,000/μL, IQR = 43,000–129,500/μL versus 110,000/μL, IQR = 66,000–170,000/μL; P < 0.0001) than children without CM.

Respiratory distress (n = 518) and lactic acidosis (n = 481).

The presence of labored or deep breathing, nasal flaring, intercostal or subcostal retractions, or tachypnea (rate > 40 breaths/minute) was directly related to disease severity but was not caused by hypoxia. Respiratory distress was observed in 61% of children with SM, but only 7% of those with uncomplicated malaria (Table 2). Hypoxia, defined as an arterial oxygen saturation < 90%, was observed in only 42 (8%) of 513 patients with RD.

Rather than hypoxia, RD was highly associated with LA (χ2 = 113, P < 0.0001). Specifically, among 516 children with RD, the median lactate level was 6.85 mM (IQR = 4.5–10.4 mM); 71% had lactate levels > 5 mM and 94% had levels > 2 mM. These results are consistent with those of previous investigators, who suggested that RD represents a respiratory compensation to LA, rather than respiratory drive from hypoxia or lung disease.8,11 Overall, among 1,903 children tested for blood lactate levels, 481 (25%) had levels > 5 mM. Lactic acidosis was found in 272 (49%) of 556 patients with SMA and in an additional 209 children (70%) with severe malaria without SMA.

Severe malaria anemia (n = 558).

Severe malaria anemia was observed in 65% of children with severe malaria. As noted by others,23 patients with SMA were younger (Figure 1B). Children with SMA had a slightly higher prevalence of splenomegaly (68% versus 51%; P < 0.0001) than those without SMA. Children with SMA also had higher absolute monocyte counts (median = 1,020/μL, IQR = 600–1,580/μL) than those without SMA (median = 547/μL, IQR = 319–886/μL) (P < 0.0001).

Severe thrombocytopenia (n = 166).

Thrombocytopenia at admission was a strong indicator of disease severity (median platelet count = 103,000/μL in patients with severe malaria versus 136,000/μL in patients with uncomplicated disease) (P < 0.0001). The proportion of children with a platelet count < 50,000/μL was nearly twice as high (19%) among those with severe syndromes than among those with uncomplicated malaria (10%) (χ2 = 38, P < 0.0001). The number of patients with CM trebled with platelet counts < 100,000/μL, suggesting that 100,000/μL may be a more informative threshold definition for severe thrombocytopenia in malaria (Figure 2).

Figure 2.

Figure 2.

Figure 2.

Cerebral malaria according to platelet count at presentation, Kampala. Uganda.

Citation: The American Society of Tropical Medicine and Hygiene 88, 4; 10.4269/ajtmh.12-0668

Hyper-parasitemia (n = 402).

The concentration of parasitized erythrocytes varied widely, and the median concentration was not statistically different between children with uncomplicated disease and those with severe disease. However, as shown in Table 2, the proportion of children with > 5% parasitized erythrocytes was significantly higher among those with severe malaria (48%) than among those with uncomplicated malaria (25%) (P < 0.0001). Nevertheless, the presence of hyper-parasitemia had a positive predictive value of only 60% for severe malaria, and the absence of hyper-parasitemia had a negative predictive value of only 65% for severe malaria. Because the definition of hyper-parasitemia depends on the ratio of infected erythrocytes to total erythrocytes, the presence of anemia increases the likelihood of being classified as hyper-parasitemic for any given absolute concentration of parasitized erythrocytes per microliter of whole blood.

Leukocytosis (n = 490).

The median leukocyte count was significantly higher in children with severe malaria (11,100/μL) than in those with uncomplicated malaria (7,800/μL) (P < 0.0001) (Table 2). Consistent with a host inflammatory response to severe disease, a leukocyte count > 10,000/μL was found in 66% of those with SMA, 67% of those with hypoxia, and 77% of those with hypoglycemia (Table 3).

Case-fatality rate.

The CFR was significantly different among patients with different severe malaria clinical features (Table 3). The most striking difference was the low CFR (2.8%) among patients with SMA than in those with CM (19%) or severe thrombocytopenia (14.5%). There were 48 deaths attributed to malaria. Major clinical features were found in the following percentages in fatal cases: LA in 79%, CM in 69%, hyper-parasitemia in 62%, severe thrombocytopenia in 50%, SMA in 31%, hypoglycemia in 33%, and hypoxia in 23%.

The relationship between CFR and the number of features present in the same patient are shown in Figure 3. The CFRs progressively increased with an increasing number of the following hallmark features of malaria: CM, LA, SMA, severe thrombocytopenia, and hyper-parasitemia. Logistic regression was used to determine the odds ratios of a fatal outcome according to the following 11 input variables: sex, age < 1.5 years, CM, LA, SMA, severe thrombocytopenia, leukocytosis, hyper-parasitemia, hypoxia, blood group A, and presence of Hb S. Five factors had significant associations with fatal outcome in the final model: CM, hypoxia, severe thrombocytopenia, leukocytosis, and LA. Test results for interactions among these five factors were found to be not significant. The results are shown in Table 4.

Figure 3.

Figure 3.

Figure 3.

Increase in case-fatality rate (CFR) with increasing number of severe malaria features, Kampala, Uganda. CFRs are shown for 855 children with one or more combinations of the following features: cerebral malaria, lactic acidosis, severe anemia, severe thrombocytopenia, or hyper-parasitemia. The x-axis separates children into five groups based on an increasing number of co-existing severe malaria features present in combination. The groups show an increasing median CFR. The size of each bubble indicates the number of persons ranging from n = 558 for the single feature of severe anemia (lower left) to n = 4 for all five features simultaneously present (upper right).

Citation: The American Society of Tropical Medicine and Hygiene 88, 4; 10.4269/ajtmh.12-0668

Table 4

Logistic regression for fatal outcome based on 798 children with severe malaria, Kampala, Uganda*

Characteristic Odds ratio 95% Confidence interval P
Cerebral malaria (CM) 10.9 4.8–25.0 < 0.0001
Hypoxia 6.9 2.5–19.1 0.0002
Severe thrombocytopenia 3.8 1.7–8.2 0.0008
Leukocytosis 3.0 1.3–6.9 0.0129
Lactic acidosis (LA) 2.4 1.0–5.5 0.0454
Blood group A 1.8 0.9–3.9 0.1077
Female sex 1.2 0.6–2.5 0.5930
Age < 1.5 years 1.1 0.5–2.5 0.8158
Hemoglobin S 1.0 0.2–6.1 0.9691
Hyper-parasitemia 0.9 0.4–1.8 0.6980
Severe malaria anemia (SMA) 0.7 0.3–1.5 0.3466
Characteristic Odds ratio 95% Confidence interval P
Cerebral malaria (CM) 13.1 6.2–27.7 < 0.0001
Hypoxia 6.9 2.6–18.8 0.0001
Severe thrombocytopenia 3.6 1.7–7.5 0.0008
Leukocytosis 2.4 1.1–5.3 0.0303
Lactic acidosis (LA) 2.4 1.1–5.4 0.0351

Inter-relationships of malaria syndromes.

Inter-relationships between major clinical features of severe malaria are shown in Table 5 and Figure 4. Clinical findings were assembled into clusters on the basis of statistically significant positive odds ratios. Two clusters of associations emerged. In the first cluster, SMA, splenomegaly, and leukocytosis demonstrated mutually significant positive associations of similar magnitude. In the second cluster, seven features demonstrated significant positive inter-relationships. Strong associations centered on the triad of death, severe thrombocytopenia, and LA. Cerebral malaria was associated with death and severe thrombocytopenia; hypoxia and hypoglycemia were associated with death and LA; and hyper-parasitemia was associated with LA and severe thrombocytopenia.

Table 5

Associations between clinical syndromes among children with severe Plasmodium falciparum malaria, Kampala, Uganda*

Characteristic CM LA SMA Severe thrombocytopenia Leukocytosis Hyper-parasitemia Hypoxia Hypo-glycemia Splenomegaly
Death 10.39 2.727 0.221 4.684 1.685 1.682 6.156 4.518 0.164
P < 0.0001 P = 0.003 P < 0.0001 P < 0.0001 P = 0.13 P = 0.10 P < 0.0001 P = 0.002 P < 0.0001
Splenomegaly 0.728 0.846 2.265 0.795 2.034 1.088 1.451 1.578
P = 0.19 P = 0.39 P < 0.0001 P = 0.31 P < 0.0001 P = 0.71 P = 0.51 P = 0.54
Hypo-glycemia 0.940 7.117 1.8133 1.512 3.849 2.4 3.837
P = 1.0 P < 0.001 P = 0.25 P = 0.46 P = 0.007 P = 0.07 P = 0.045
Hypoxia 1.214 2.352 0.596 1.479 1.590 1.263
P = 0.56 P = 0.017 0.1 P = 0.32 P = 0.20 P = 0.52
Hyper-parasitemia 1.069 2.152 0.858 1.96 1.423
P = 0.73 P < 0.0001 P = 0.3 P < 0.0001 P = 0.014
Leukocytosis 0.562 1.454 2.903 0.439
0.0001 P < 000.1 P < 0.0001 P < 0.0001
Severe thrombocytopenia 2.556 2.490 0.268
P < 0.0001 P < 0.0001 P < 0.0001
SMA 0.081 0.394
P < 0.0001 P < 0.0001
LA 0.609
P = 0.004

Figure 4.

Figure 4.

Figure 4.

Inter-relationships of clinical and laboratory findings in 855 children with severe malaria, Kampala, Uganda. The odds ratios for association between pairs of clinical and laboratory findings were determined for 855 children with severe malaria. Those features with a statistically significant positive odds ratio of association are shown. The reciprocal of the loge of the odds ratio defines the relative distance between spheres, and the number of persons with each feature defines the volume of each sphere. Two clusters of associations were observed. A, Cluster centered on severe malaria anemia (SMA). B, Cluster of seven features. CM = cerebral malaria; LA = lactic acidosis. Thrombocytopenia = platelet count < 50,000/μL.

Citation: The American Society of Tropical Medicine and Hygiene 88, 4; 10.4269/ajtmh.12-0668

Discussion

Using a standardized assessment, we have analyzed the clinical features at hospitalization of 1,933 children with acute malaria at Mulago Hospital in Kampala, Uganda. We confirmed results of previous reports that SMA affects younger children and CM affects older children with malaria; that LA is found both in association with SMA and independent of SMA; and that RD was unrelated to hypoxia. Our data update existing information on risk factors associated with fatal outcomes in severe malaria.

The three largest recent studies on presenting features in malaria are those of Dzeing-Ella and others,15 Issifou and others,16 and Ranque and others,17 each of which enrolled children more than a decade ago. Our study agrees with the findings of those reports but includes a larger number of children with severe malaria. In addition, we recorded oxygen saturations, measured blood lactate levels for > 10 times as many children, and were able to analyze the independent contributions of thrombocytopenia and leukocytosis to outcomes. Regarding fatal outcomes, we confirm previous findings by many investigators that CM is the principal cause of malaria death; that SMA has a low risk of death if transfusions are available; that CFRs increase in proportion to increasing numbers of co-existing severe malaria features; and that LA and hypoglycemia are associated with fatal outcomes. The CFR for children with CM (19%) was similar to that reported by Marsh and others in 1995,2 suggesting little therapeutic advance for this deadly syndrome. We extend existing reports by identifying with logistic regression five factors associated with fatal outcomes: CM, hypoxia, severe thrombocytopenia, leukocytosis, and LA.

The presence of severe thrombocytopenia was a clinically important finding in our study with prognostic significance. Children with severe malaria had lower median platelet counts than those with uncomplicated malaria (Table 2). In logistic regression analysis, death was 3.6 times more likely in the presence of severe thrombocytopenia. Recent interest has focused on the finding by McMorran and others29 that growth of P. falciparum in vitro was inhibited by co-culture with platelets. However, their non-flow, co-culture system was unable to assess the role of platelets in the cytoadhesion of parasitized erythrocytes to endothelium. Our clinical data support the view that thrombocytopenia is associated with poor outcomes30 and are consistent with the hypothesis that platelets actively participate in the pathophysiology of cytoadhesion in malaria.26,3136

As shown in Figure 4, we determined inter-relationships among the major clinical features of SM. We observed two clusters of relationships, one cluster in children with SMA, and a second cluster centered on death, severe thrombocytopenia, and LA. These inter-relationships are consistent with the three original major syndromes described by Marsh and others2 (CM, SMA, and RD) and with three potential pathophysiologic pathways shown in Figure 5. One pathway emphasizes anemia that accompanies some patients with malaria. With blood transfusion, children with SMA can be rescued and fatal outcomes averted.6 Without transfusion, severe anemia will result in insufficient tissue oxygenation, LA, and RD. A second pathway emphasizes cytoadhesion and microvascular ischemia in the central nervous system resulting in CM. In our dataset, severe thrombocytopenia was strongly associated with CM (Figure 2, Figure 4, and Table 5), suggesting an important role for platelet-mediated cytoadhesion in the cerebral vasculature as suggested by several authors.31,32,34,37 A third pathway, also directly associated with severe thrombocytopenia, is systemic LA in the absence of CM or SMA (Figure 4 and Table 5). Lactic acidosis with accompanying RD presumably results from microvascular tissue ischemia outside the central nervous system, and in severe cases is associated with hypoglycemia and death. Further research to identify which host or parasite factors favor cytoadhesion in the cerebral vasculature versus the non-cerebral circulation is expected to be of value in guiding new therapies.

Figure 5.

Figure 5.

Figure 5.

Possible pathophysiologic pathways in fatal Plasmodium falciparum malaria, Kampala, Uganda. The inter-relationships of clinical features of malaria and the identification of factors with significant odds ratios for fatal outcomes suggest distinct pathophysiologic pathways in children with severe disease.

Citation: The American Society of Tropical Medicine and Hygiene 88, 4; 10.4269/ajtmh.12-0668

Our study had the following limitations. Results are based only on children who were hospitalized. Thus, our data do not reflect general prevalence rates for children at risk for malaria. Serial laboratory data and clinical follow-up data were not collected. We did not collect data for renal function, levels of malaria pigment found in leukocytes, cytokines, retinal examination in all patients with suspected CM or the relative distribution of parasite maturity in peripheral blood. However, none of these features was considered essential in the clinical assessment of malaria by a recent panel of experts.24

In summary, we update presenting features of pediatric malaria on the basis of a prospective, uniform, clinical and laboratory assessment of approximately 2,000 children treated at an urban medical center in Uganda. Our data emphasize the clinical distinction between uncomplicated and severe malaria, report the prevalence of cardinal features that characterize syndromes of severe malaria, quantify clustered inter-relationships among malaria syndromes, and identify the major risk factors for fatal outcomes. We hope that these results will not only assist in the care of children with malaria, but may also prove valuable in the planning and assessment of future research.

ACKNOWLEDGMENTS

We thank all pediatric patients and their families who agreed to participate in this study; the staff of the Molecular Biology Laboratory of the University of Makerere University–University of California San Francisco (Dr. Sammuel Nsobya and the parasitology technologists); Dr. Francis Ssali (Joint Center for Clinical Research, Kampala); Dr. Sarah Kiguli-Walube (Department Head of Paediatrics at Makerere University College of Health Sciences); Dr. Robert Opoka (Medical Director of Acute Care Unit, Mulago Hospital); Jolly Rubambarama (Head registered nurse at the Acute Care Unit of Mulago Hospital); the malaria blood film screening staff at the Acute Care Unit (Edson Sabuni, Josephine Birungi, Rehema Namwanje, Timothy Pande, David Balamusani, Stephen Ikodi, Moses Kizito, and Vincent Sekibala); the specimen transport chain management in Kampala (Abdu Mwanje); Dr. Dorothy Kyeyune (Director of the Uganda National Blood Transfusion Service; HIV testing laboratory staff (Dr. Tony Mazzulli and Lilian Law at Mount Sinai Hospital in Toronto) for their contributions to this study; Avogadro, an open source molecular builder for providing a visualization tool, version 1.1.0 (http://avogadro.openmolecules.net/), which was used to prepare the digital model in Figure 4; Eileen Selogie (Enet Answers) (http://www.enetanswers.com/) for developing the animation for public viewing; and Masimo Corporation, Whatman Corporation, Bayer, Ortho Clinical Diagnostics, Nonin Corporation, and Heart to Heart International for providing equipment and supplies.